Allergan plc

What's your position on ?
Why are you ish?
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Wed, Feb. 3, 4:35 AM
    • Pfizer (NYSE:PFE) is insisting that its $160B takeover of Allergan (NYSE:AGN) will not be thwarted by political opposition, amid criticism that the so called tax-inversion would cost the U.S. Treasury billions of dollars in future revenues.
    • "Under current law, I do not believe there is any reason why the deal will not close - full stop," Pfizer CEO Ian Read declared.
    • He also reiterated a plan to delay until 2018 a decision on whether to break the enlarged Pfizer-Allergan into two or three smaller companies, but said he would be open to offers for its generics business.
    | Wed, Feb. 3, 4:35 AM
  • Dec. 3, 2015, 11:53 AM
    • According to sources close to the matter, Teva Pharmaceutical Industries (TEVA +2.2%) is currently divesting $1B in assets in order to address antitrust concerns related to its intended $40.5B acquisition of Allergan's (AGN -0.2%) generics business, Actavis Generics. The move will help ensure that the deal goes through in Q1 as planned.
    • Previously: Teva to buy Allergan Generics for $40.5B (July 27)
    | Dec. 3, 2015, 11:53 AM | 2 Comments
  • Nov. 23, 2015, 7:48 AM
    • It's official. Pfizer (NYSE:PFE) and Allergan (NYSE:AGN) agree to merge in a $160B deal, the largest inversion transaction on record. AGN shareholders will receive 11.3 shares of the combined company for each AGN share while PFE shareholders will receive one share of the combined firm for each PFE share. The deal should close in H2 2016. After the merger, the company will do business as "Pfizer plc" and trade under the "PFE" symbol. It will be domiciled in Ireland (pro forma adjusted effective tax rate expected to be 17 - 18%).
    • Pfizer shareholders will own ~56% of the combined firm while Allergan shareholders will own ~44%. Pfizer chief Ian Read will be Chairman & CEO while Allergan chief Brent Saunders will be President & COO.
    • The merger should be neutral to Pfizer's non-GAAP EPS in 2017, accretive in 2018, more than 10% accretive in 2019 and accretive in the high teens in 2020. Operating cash flow should exceed $25B beginning in 2018.
    • The company will make a decision on splitting its innovative and established businesses no later than the end of 2018.
    • Separately, Pfizer will execute a $5B share repurchase program in H1 2016. It has ~$5.4B remaining on its previously announced buyback plan.
    • Pfizer will host a conference call this morning at 8:30 am ET to discuss the transaction.
    • Slide presentation 
    | Nov. 23, 2015, 7:48 AM | 60 Comments
  • Nov. 22, 2015, 8:23 PM
    • In what would be the largest "inversion" deal ever, the boards of Pfizer (NYSE:PFE) and Allergan (NYSE:AGN) have agreed to merge, reports the WSJ, with an official announcement perhaps coming tomorrow.
    • The deal, of course, comes days after Treasury issued new rules aimed at curbing such deals, but analysts say the new measures don't put this particular merger at risk. Global antitrust regulators will be sure and have their say, though.
    • Pfizer CEO Ian Read - an outspoken critic of high U.S. corporate tax rates - will lead the combined company, says the Journal, with Allergan CEO Brent Saunders serving as president and COO.
    • The final terms would have Allergan shareholders receiving 11.3 Pfizer shares for each share of AGN they own, say sources, and there's also a small cash component. Pfizer closed Friday at $32.18, making just the stock portion worth $363.63 vs. Allergan's close of $312.84.
    • The companies are planning for seven to nine months before closing. The combined entity is then expected to evaluate splitting into two businesses - one focused on patent-protected products and the other on drugs that have already lost it (or are close to).
    • Previously: Pfizer said to be near deal to buy Allergan for as much as $380/share (Nov. 18)
    • Previously: Will the new inversion rules derail a Pfizer-Allergan deal? (Nov. 20)
    | Nov. 22, 2015, 8:23 PM | 90 Comments
  • Nov. 20, 2015, 2:24 AM
    | Nov. 20, 2015, 2:24 AM | 11 Comments
  • Nov. 19, 2015, 11:14 AM
    | Nov. 19, 2015, 11:14 AM | 29 Comments
  • Nov. 18, 2015, 8:30 PM
    • Pfizer (NYSE:PFE) is in advanced talks to buy Allergan (NYSE:AGN) for $370-380/share, according to multiple reports.
    • The companies are aiming to announce an agreement as soon as Monday, but the U.S. Treasury Department’s letter on tax inversion deals could delay the final agreement and change the terms.
    • A deal at $380/share would value AGN at nearly $150B and be the biggest health care deal ever, as well as the largest acquisition this year.
    | Nov. 18, 2015, 8:30 PM | 21 Comments
  • Oct. 29, 2015, 6:31 AM
    • Allergan (NYSE:AGN) is up 15% premarket on light volume on the news that it is in talks with Pfizer (NYSE:PFE) about a possible merger. If the deal goes through, it would create the world's largest healthcare firm with a market value of $330B, larger than Johnson & Johnson's (NYSE:JNJ) market cap of $278B.
    • A lower tax bill is one of the reasons Allergan is an attractive target for Pfizer considering the Botox maker is domiciled in tax-friendly Dublin. The U.S. government clamped down on tax inversion deals last year which scuppered the AbbVie/Shire deal so it is unclear how this might effect Pfizer's ability to change its domicile.
    • Potential Pfizer takeover targets GlaxoSmithKline (NYSE:GSK) and Shire (NASDAQ:SHPG) are both down slightly in premarket trading.
    • Update: Both Pfizer and Allergan confirm the commencement of "friendly" discussions regarding a potential combination.
    | Oct. 29, 2015, 6:31 AM | 14 Comments
  • Oct. 19, 2015, 8:57 AM
    | Oct. 19, 2015, 8:57 AM
  • Sep. 10, 2015, 1:05 PM
    • Thinly traded ZS Pharma (ZSPH +11.7%) is up on a 5x surge in volume as traders take positions hoping for good news, like being acquired. The bullishness was stoked when the company canceled its presentation and one-on-one meetings at a Citi investor conference and has not returned calls regarding the reason.
    • Bulls cite the similarity to Kythera, which canceled an appearance at a conference several months ago and announced its takeover by Allergan (AGN) shortly thereafter.
    | Sep. 10, 2015, 1:05 PM | 3 Comments
  • Sep. 3, 2015, 5:34 PM
    • Allergan (NYSE:AGN) is acquiring AqueSys, a clinical-stage developer of ocular implants that lower intraocular pressure related to glaucoma, for $300M up-front + "regulatory approval and commercialization milestone payments related to AqueSys' lead development programs." The deal is expected to close in Q4.
    • Allergan: "The acquisition of AqueSys adds XEN45, a soft shunt that is implanted in the subconjunctival space in  the eye through a minimally invasive procedure with a single use, pre-loaded proprietary injector. The proprietary XEN45 technology facilitates aqueous fluid flow to lower Intra-Ocular Pressure (IOP) while protecting against the potential for hypotony (IOP that is too low) that is associated with current subconjunctival procedures."
    • XEN45 has been approved for use in the EU, Turkey, Canada, and Switzerland.  FDA approval is expected by late 2016 or early 2017.
    | Sep. 3, 2015, 5:34 PM
  • Aug. 5, 2015, 8:31 AM
    | Aug. 5, 2015, 8:31 AM
  • Jul. 28, 2015, 2:38 AM
    • So what's Allergan (NYSE:AGN) doing with all that cash from the Teva deal? CEO Brent Saunders plans to use the money to increase the size of the firm's existing drug business, expand into new therapy areas and pursue larger deals.
    • When asked if Allergan planned to spend the cash within 18 months, Saunders replied that he would, as long as the company could maintain its investment-grade credit rating.
    • Possible targets: Biogen (NASDAQ:BIIB), AbbVie (NYSE:ABBV) and Amgen (NASDAQ:AMGN).
    • Previously: Teva to buy Allergan Generics for $40.5B (Jul. 27 2015)
    | Jul. 28, 2015, 2:38 AM | 11 Comments
  • Jul. 27, 2015, 7:09 AM
    • Mylan (NASDAQ:MYL) drops 12% premarket on increased volume in response to Teva's (NYSE:TEVA) $40.5B deal for Allergan's (NYSE:AGN) generics business, dashing investors' hopes that it would pursue its hostile bid for Mylan.
    • In a statement, Mylan reaffirms its interest in Perrigo. A vote on the combination by Mylan shareholders is expected to happen in the next few weeks.
    | Jul. 27, 2015, 7:09 AM | 3 Comments
  • Jul. 27, 2015, 5:29 AM
    • Besides for its recent deal with Teva, Allergan (NYSE:AGN) said on Sunday it would acquire biotech company Naurex, which is developing a fast-acting antidepressant.
    • "Depression remains one of the largest unmet areas of medical need. When you think about existing therapies, they have modest effects with lots of side effects," said Brent Saunders, Allergan's chief executive.
    • The $560M all-cash transaction is expected to close by year-end.
    | Jul. 27, 2015, 5:29 AM | 2 Comments
  • Jul. 27, 2015, 5:19 AM
    • Teva Pharmaceuticals (NYSE:TEVA) has agreed to buy the generic-drug business of Allergan (NYSE:AGN) for about $40.5B in cash and stock, ending its effort to acquire rival Mylan (NASDAQ:MYL).
    • Allergan will receive $33.75B in cash and shares in Teva valued at $6.75B, giving it a 10% stake in the enlarged company.
    • The acquisition further extends a wave of mergers that has swept over the healthcare industry. Pharmaceutical deals so far this year have topped $180B, on pace to beat the $200B announced in 2014.
    • TEVA +12.1% premarket
    | Jul. 27, 2015, 5:19 AM | 14 Comments
Company Description
Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.